COVID-19 vaccine responses in PIDD subjects

COVID-19 vaccine responses in PIDD subjects

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to learn more about the immune response patients with X-linked Agammaglobulinemia (XLA) have to COVID-19 vaccination. We will compare their immune responses to those of healthy people who have normal immune systems. Better understanding of cellular responses to COVID-19 vaccines by XLA patients is important since XLA patients cannot make antibodies to vaccines. If you are interested, please contact the study team at XLACOVIDvax@duke.edu.

Who Can Participate?

Eligibility

People with XLA and healthy male participants are both eligible to join this study. We are enrolling XLA patients who:
  • Are diagnosed with XLA based on absence of B cells or genetic confirmation
  • Are being treated with immunoglobulin replacement without recent dose change
  • Have not received a COVID-19 vaccine, but plan to get one
  • Have no signs or symptoms of COVID-19 infection
  • Have not received any other vaccines within 2 weeks of the COVID-19 vaccine
We are enrolling healthy male participants who:
  • Are 12 years and older
  • Have not received a COVID-19 vaccine, but plan to get one
  • Have no signs or symptoms of COVID-19 infection
  • Do not have any medical conditions that affect the immune system
  • Are not taking any medicine that affects the immune system
  • Have not received any other vaccines within 2 weeks of the COVID-19 vaccine

Age Range

1-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
Yes

What is Involved?

Description

If you choose to join the study, you will:
  • Have an eligibility assessment made by the study team
  • Make an appointment for COVID-19 vaccination
  • Have blood draws 7, 21, 120, and 365 days after your second dose of vaccine
  • Participate in virtual, telephone, or in-person follow up visits
  • Be monitored by the study team for any symptoms you might experience while in the study

Locations

Duke University Hospital
Other

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

Vaccine-induced SARS-CoV-2-specific T cell responses in patients with Primary Immune Deficiency Disease

Principal Investigator

John
Sleasman

Protocol Number

PRO00108422

NCT ID

NCT05321407

Enrollment Status

Open to Enrollment
ClinicalTrials.gov